Skip to content

Design Therapeutics, Inc.

DSGN

CIK 0001807120

← back to feed
Revenue (TTM)
$226K
Q1 Apr 2026
Net Income (TTM)
−$71.43M
−40.7% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.24
−38.6% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-35,842.5%
Q1 Apr 2026
Net Margin
-31,606.6%
Q1 Apr 2026
Free Cash Flow (TTM)
−$63.44M
Q1 Apr 2026
Cash
$12.77M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
62.46M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings